smooth muscle induced lncRNA, enhancer of proliferationGenealiases: []
Q-omics provides the consensus-scored SMILR profile across patient tissues and cancer cell-line models. SMILR expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SMILR is differentially expressed in 9, with the highest sampling consensus in LUSC. Additionally, SMILR RNA expression shows 11,326 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, LUSC, and TGCT as cancer lineages where SMILR shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SMILR — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SMILR survival associations across molecular data types. SMILR RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SMILR RNA expression–survival associations across cancer types. High SMILR expression shows unfavorable associations in ACC, KIRC, KIRP, UVM and PAAD, but favorable associations in LIHC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for SMILR RNA expression.
This table summarizes SMILR tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for SMILR. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SMILR shows higher tumor expression in LUSC, LIHC, COAD, LUAD, BRCA and KIRC. The LUSC box plot shows higher SMILR RNA expression in tumor versus normal tissue (log2 FC = +0.887, t-test p < 0.001).
This table shows molecular features associated with SMILR in patient tissues and cancer cell lines. In patient samples, SMILR shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
